Actively Recruiting
Study of MyeloGen Gene Panel for Genetic Testing in Adults with Myeloid Blood Cancers
Led by Christopher Reilly · Updated on 2026-04-24
200
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility of using the investigational MyeloGen Gene Panel to conduct germline genetic testing in adults diagnosed with myeloid malignancies. This prospective, single-arm study aims to learn how to best incorporate routine genetic testing into clinical care for people with blood cancers, regardless of their personal or family history. The study is sponsored by the Broad Clinical Laboratory and led by Christopher Reilly. Participants will undergo a baseline visit including questionnaires, watching an educational video, and a punch skin biopsy to collect skin fibroblasts for genetic testing. Negative genetic test results will be sent by mail, while positive results will be followed up with an appointment with a genetic counselor or physician. Participants will complete post-results questionnaires and have their medical records followed for up to two years from the time of consent. During the study, participants will attend in-clinic visits for assessments and provide skin biopsy samples. Researchers will measure the successful completion rate of the testing within 10 weeks and track the number of participants with positive genetic findings within 12 weeks. Patient-reported outcomes based on surveys will be collected up to 60 days after testing. The study includes follow-up through medical records for up to two years to monitor outcomes and care.
CONDITIONS
Brief Title
Germline Testing for Predisposition to Myeloid Malignancies
Research Team
C
Christopher R Reilly, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here